Natco's Q4FY21 revenues de-grew 27.2% YoY to Rs. 331.3 crore due to decline across verticals. Export formulations declined 27.6% YoY to Rs. 158.8 crore due to significant drop in Tamiflu sales. Domestic formulations de-grew 20.3% to Rs. 81.8 crore amid a sharp fall in oncology sales. API business declined 26.6% YoY Rs. 70.8 crore. EBITDA margins contracted 521 bps YoY to 23%, mainly due to higher employee cost. EBITDA fell 40.6% YoY to Rs. 76.2 crore. Ensuing PAT declined 43.7% YoY to Rs. 53 crore.
For details, click on the link below: Link to the report
Shares of NATCO PHARMA LTD. was last trading in BSE at Rs.1098.05 as compared to the previous close of Rs. 1095.15. The total number of shares traded during the day was 15933 in over 1161 trades.
The stock hit an intraday high of Rs. 1115.05 and intraday low of 1072. The net turnover during the day was Rs. 17514755.